Focus: Coherus Oncology is a biotechnology company focused on oncology and biosimilars, headquartered in Redwood City, CA. The company operates a diversified pipeline spanning early-stage immuno-oncology programs and late-stage biosimilar development.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Coherus Oncology offers portfolio depth and commercial upside potential, but lacks revenue foundation and faces investor confidence challenges; best suited for risk-tolerant early-stage professionals betting on mid-2026 clinical readouts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Coherus Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Coherus Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
CHRS - Coherus Oncology Inc Stock Price and Quote - Finviz
CHRS - Coherus Oncology Inc Stock Price and Quote Finviz
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncolog - AD HOC NEWS
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncolog AD HOC NEWS
Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) - Seeking Alpha
Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) Seeking Alpha
Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives - simplywall.st
Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives simplywall.st
Coherus Oncology posts $11.8M Q1 revenue, advan... - Pluang
Coherus Oncology posts $11.8M Q1 revenue, advan... Pluang
Coherus Oncology (CHRS) boosts LOQTORZI sales and cash with Q1 2026 stock offering - Stock Titan
Coherus Oncology (CHRS) boosts LOQTORZI sales and cash with Q1 2026 stock offering Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo